Clinical Policy: External Diabetic Devices (Omnipod)
Customize your policy alerts
Sign up for Delaware First Health Policy DE.PHAR.534 alerts
Get alerted when Policy DE.PHAR.534 changes without checking for updates manually.
Monitor payer policy activity
Policy governs prior authorization and medical necessity criteria for Omnipod insulin delivery systems (Omnipod DASH, Omnipod 5, Omnipod GO) for Delaware First Health Medicaid members and describes initial and continued coverage requirements.
No material clinical or coverage changes in this revision.
Coverage Criteria — Omnipod Systems
Initial Approval — Omnipod GO
Covered when ALL of the following are met:
Approval duration: 6 months; Number of Pods does not exceed 10 per month (requests >10 require clinical rationale and documentation).
Initial Approval — Omnipod DASH/Omnipod 5
Covered when ALL of the following are met:
Approval durations: Pods 6 months, device 30 days.
Continued Therapy — Diabetes Mellitus
Covered when ALL of the following are met:
Approval durations (Medicaid): Omnipod DASH/Omnipod 5 pods 12 months, device 30 days; Omnipod GO pods 12 months.
Non–FDA-approved indications for Omnipod systems that are not specifically addressed in this policy are not covered unless the request includes sufficient documentation of efficacy and safety in accordance with the plan's off‑label use policy CP.PMN.53 or other applicable evidence-of-coverage documents.
Use of Omnipod DASH, Omnipod 5, and Omnipod GO is not recommended for members who are unable to monitor blood glucose as recommended by their provider, unable to maintain regular contact with their healthcare provider, or unable to use the system according to manufacturer instructions. The policy specifies that Omnipod DASH users should perform at least 4 blood glucose tests per day as recommended. Omnipod 5 and Omnipod GO have additional suitability considerations: Omnipod 5 is not recommended for members taking hydroxyurea or for those without adequate hearing or vision to recognize system alerts; Omnipod GO is not recommended for those without adequate hearing or vision to perceive Pod lights and sounds. Similarly, InPen is not intended for members unwilling or unable to test blood glucose, maintain diabetes self-care skills, or attend regular clinical follow-up.
HCPCS codes listed in this policy are provided for informational purposes only. The code A9274 is described as an external ambulatory insulin delivery system (disposable Pod) and E0784 as an external ambulatory infusion pump (PDM device); however, the policy notes that these codes do not apply to Omnipod DASH or Omnipod 5 because those products are available only through pharmacy distribution. Providers should verify benefit and billing pathways (medical vs pharmacy) and prior authorization requirements with the plan prior to ordering or submitting claims.
Additional HCPCS/NDC applicability clarifications in the policy: A9274 and E0784 are used to describe Omnipod systems generally but do not apply to Omnipod DASH or Omnipod 5 when those products are dispensed via pharmacy channels. The supply code A4211 is noted as non‑specific and may be applied to other devices (for example, InPen). The policy also clarifies that code S5561 (reusable insulin delivery pen) does not apply to InPen. Inclusion or exclusion of these codes does not guarantee coverage; providers must reference current coding guidance before claim submission.
Coding and Identifiers
| 08508200005 | Omnipod DASH 5 Pack Pods. |
| 08508200000 | Omnipod DASH PDM Kit. |
| 08508200032 | Omnipod DASH Intro Kit. |
| 08508300021 | Omnipod 5 G6 Refill 5 Pack Pods. |
| 08508300001 | Omnipod 5 G6 Intro Kit. |
| 08508300050 | Omnipod 5 G7 Intro Kit (Gen 5). |
| 08508300053 | Omnipod 5 G7 Pods (Gen 5). |
| 08508200005 | Omnipod DASH 5 Pack Pods |
| 08508200000 | Omnipod DASH PDM Kit |
| 08508200032 | Omnipod DASH Intro Kit |
| 08508300021 | Omnipod 5 G6 Refill 5 Pack Pods |
| 08508300001 | Omnipod 5 G6 Intro Kit |
| 08508300050 | Omnipod 5 G7 Intro Kit (Gen 5) |
| 08508300053 | Omnipod 5 G7 Pods (Gen 5) |
Provider Actions, Documentation & Billing Guidance
Prior authorization required for Omnipod systems
Prior authorization is required for requests for Omnipod DASH, Omnipod 5, and Omnipod GO insulin delivery systems.
Order device-specific starter kits and refill packs
Order the product type consistent with payer product availability: Omnipod DASH starter kits and 5‑pack Pods; Omnipod 5 Intro Kit and 5‑pack refill Pods; Omnipod GO available in Pod pack sizes (e.g., packs of 5 in multiple quantity options). These supplies may be subject to medical benefit ordering and prior authorization per payer processes.
- Omnipod DASH: Starter Kit (PDM plus compatible BGM) and Omnipod Pack 5 (packs of 5 Pods).
- Omnipod 5: Intro Kit (Controller + CGM) and Refill 5 Pack Pods.
- Omnipod GO: Packs of 5 Pods in multiple pack-size options.
Codes and NDCs are informational — verify with payer
Codes and NDCs listed in the policy are provided for informational purposes only; verify prior authorization and coding requirements with the plan prior to submission.
- HCPCS and NDC listings in this policy do not guarantee coverage.
Confirm benefit coverage and PA requirements with member documents
Verify member benefit coverage and whether prior authorization is required for HCPCS codes A9274, E0784, and A4211 by checking the member's coverage documents and current coding guidance before submitting a request or claim.
- Reference the member's evidence of coverage/certificate of coverage and payer coding guidance.
Prior use of CSII or ≥3 daily injections required for DASH/5
For initial Omnipod DASH or Omnipod 5 requests, submit documentation that the member has used either a continuous insulin delivery system for ≥6 months or multiple daily injections (≥3 daily injections) for ≥6 months, with evidence of suboptimal control as specified in the criteria.
- Document at least 6 months of CSII use OR ≥6 months of MDI with ≥3 injections/day.
- Provide evidence of suboptimal control (examples listed in policy: repeated hypoglycemia, DKA, wide excursions, hypoglycemia unawareness, HbA1c ≥7.0, dawn phenomenon).
Consider listed therapeutic alternatives
Consider alternative insulin delivery systems or injectable antidiabetic agents listed in the policy's therapeutic alternatives table before or instead of Omnipod systems as clinically appropriate.
- Examples include other insulin pumps (t:slim X2, MiniMed systems), V‑Go wearable insulin delivery, and various injectable antidiabetic agents listed in the policy appendices.
No step therapy specified
No step therapy requirements are specified in this policy for Omnipod requests.
Provide clinical documentation supporting all approval criteria
Submit office chart notes, laboratory results, and other clinical documentation demonstrating the member meets all approval criteria (diagnosis, prescribing provider, prior therapy, BG monitoring frequency, pod/device quantities, and response to therapy).
- Include documentation of BG monitoring ≥4 times/day for the last 6 months when required.
- Provide clinical rationale for requests exceeding 10 Pods/month.
Program initial device settings and provide trainer-led instruction
For initial Omnipod DASH system use, program the initial PDM settings and meet with the patient and an Omnipod System Trainer to program and prime the first Pod.
- Ensure each Pod is filled with at least 85 units for initial programming and primed using the PDM.
- Document trainer visit and initial programming in the medical record.
Use cited FDA 510(k) summaries and user guides as references
Reference device FDA 510(k) summaries and manufacturer user guides when documenting device use, indications, and training (e.g., Omnipod/Omnipod DASH/Omnipod 5/Omnipod GO 510(k) summaries and user guides cited in the policy).
- Omnipod DASH and Omnipod 5 510(k) summaries and user guides are cited in the policy.
- Omnipod GO 510(k) summary and user guide are also referenced.
Coverage subject to member's plan documents
Coverage decisions are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents and applicable state and federal requirements; the policy does not guarantee payment.
Incomplete documentation or unsupported off‑label requests risk denial
Requests lacking documentation that the member meets approval criteria, or requests for non‑FDA indications without sufficient off‑label documentation per CP.PMN.53, may be denied.
- Provide off‑label efficacy/safety documentation per off‑label use policy when applicable.
Do not request for patients unable to perform monitoring or follow‑up
Do not recommend Omnipod systems for patients who are unable to monitor glucose as recommended, unable to maintain contact with their healthcare provider, or unable to use the system per instructions; such use may lead to denial.
- For Omnipod DASH, monitoring at least 4 BG tests/day is specified.
Patient safety limitations and contraindications to consider
Avoid Omnipod 5 use in patients taking hydroxyurea or those with inadequate hearing/vision that prevent recognition of alerts; InPen is not intended for patients unwilling or unable to perform recommended self‑care and monitoring.
- Hydroxyurea can cause falsely elevated CGM values and risk insulin overdelivery with Omnipod 5.
Coding listings do not guarantee coverage
Inclusion or exclusion of codes in this policy does not guarantee coverage; providers must reference the most up‑to‑date professional coding guidance prior to claim submission.
Verify coding guidance before claims
Before submitting claims, confirm current coding guidance and payer rules; listed HCPCS/NDC codes are informational and not a guarantee of payment.
Background — Omnipod Systems Overview
Omnipod systems are adhesive, disposable, tubeless insulin pumps intended to provide continuous subcutaneous insulin infusion for diabetes management. The product family includes Omnipod DASH and Omnipod 5, which are indicated for persons with type 1 diabetes and insulin-requiring type 2 diabetes (with age specifications for Omnipod 5), and Omnipod GO, which is targeted to adults with type 2 diabetes requiring basal insulin. Omnipod 5 integrates with a compatible continuous glucose monitor (CGM) and provides automated insulin adjustments (adjusting every 5 minutes using predicted glucose). Pod devices have a minimum fill capacity of 85 units (capacity up to 200 units) and typical wear duration up to 1–3 days; Omnipod GO has a specified maximum daily dose of 40 units per day under the product parameters described in the policy.
Definitions and Code Explanations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.